Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Chromothripsis and DNA Repair Disorders

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence of anxiety and depression symptoms in pregnant women with type 2 diabetes and the impact on glycaemic control

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Co-existence of starvation ketoacidosis and hyperthyroidism in early pregnancy: a case report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Louise Vedtofte
  • Emilie Bahne
  • Signe Foghsgaard
  • Jonatan I Bagger
  • Camilla Andreasen
  • Charlotte Strandberg
  • Peter M Gørtz
  • Jens J Holst
  • Henning Grønbæk
  • Jens A Svare
  • Tine D Clausen
  • Elisabeth R Mathiesen
  • Peter Damm
  • Lise L Gluud
  • Filip K Knop
  • Tina Vilsbøll
Vis graf over relationer

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated the effect of the GLP-1 analogue liraglutide on NAFLD features in women with pGDM. Eighty-two overweight/obese, nondiabetic women with pGDM were included. We performed abdominal ultrasound, transient elastography with controlled attenuation parameter (CAP), and blood sampling at baseline and after 1 year. Thirty-seven women were randomized to liraglutide (1.8 mg once-daily) and 45 to placebo. Based on the ultrasound scan, 18 women (22%) had ultrasound-verified NAFLD at baseline and of these, 10 (56%) received liraglutide treatment. After 1 year, eight participants no longer had steatosis, four in each treatment group. The number of participants who developed NAFLD was similar in the two treatment groups; five in the liraglutide group and six in the placebo group (p = 0.74). Compared to placebo, liraglutide reduced the CAP-assessed intrahepatic fat content (-28 (-44;-11) vs. 2 (-13;18) dB/m, p < 0.01) and body weight (-4.7 (-6.4;-2.9) vs. -1.4 (-3;0.3) kg, p < 0.01). One-year's liraglutide treatment had no effect on the presence of ultrasound-diagnosed NAFLD in overweight/obese nondiabetic women with pGDM, but reduced body weight and steatosis assessed by transient elastography with CAP.

OriginalsprogEngelsk
ArtikelnummerE3213
TidsskriftJournal of Clinical Medicine
Vol/bind9
Udgave nummer10
ISSN2077-0383
DOI
StatusUdgivet - 6 okt. 2020

ID: 61008291